Electromedical Technologies Announces Preliminary Unaudited Revenue for Q4 and FY 2022 and update on operations

March 14, 2023

SCOTTSDALE, Ariz., March 14, 2023 /PRNewswire/ — Electromedical Technologies, Inc. (OTC-QB: EMED) (“Electromedical” or the “Company”), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable, and acute pain through frequency and electro-modulation, is pleased to announce preliminary unaudited financial performance data for the three months and twelve months ended December 31, 2022.

Read more at prnewswire.com

Related news for (EMED)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.